Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2003
11/25/2003US6652855 Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
11/25/2003US6652854 Administering agents that hinder CD30/CD30L (CD30L=ligand of CD30) binding; animal model of arthritis for drug screening
11/25/2003US6652851 Cloning and recombinant production of polistinae venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon
11/25/2003US6652848 Dendritic cell hybrids
11/25/2003CA2194166C Multi-stage cascase boosting vaccine
11/20/2003WO2003096017A1 Methods and compositions for inducing an immune response
11/20/2003WO2003095667A2 Autoimmune conditions and nadph oxidase defects
11/20/2003WO2003095662A2 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system
11/20/2003WO2003095656A1 Recombinant fowlpox virus
11/20/2003WO2003095634A1 Pax-5-deficient pro-b-cells, methods of producing them and the use of such cells in human therapy
11/20/2003WO2003095613A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/20/2003WO2003095498A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003WO2003095486A1 Use of a peptide derived from the beta-subunit of hcg in order to generate an anti-tumour ctl-type response
11/20/2003WO2003095457A1 Adenosine a3 receptor modulators
11/20/2003WO2003095452A1 Substituted pyrroline kinase inhibitors
11/20/2003WO2003095425A1 Cyanopyrrolidine derivatives
11/20/2003WO2003094991A1 Medical products comprising a haemocompatible coating, production and use thereof
11/20/2003WO2003094990A1 Compounds and method for coating surfaces in a haemocompatible manner
11/20/2003WO2003094963A2 Methylated immunostimulatory oligonucleotides and methods of using the same
11/20/2003WO2003094957A2 Methods of therapy for inducing tolerance
11/20/2003WO2003094952A1 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
11/20/2003WO2003094950A2 A method of inhibiting the emigration of cells from the intravascular compartment into tissues
11/20/2003WO2003094946A1 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
11/20/2003WO2003094911A1 Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
11/20/2003WO2003094861A2 Bis-benzimidazoles and related compounds as potassium channel modulators
11/20/2003WO2003094850A2 Lipid a and other carbohydrate ligand analogs
11/20/2003WO2003094840A2 Induction of antigen specific immunologic tolerance
11/20/2003WO2003094836A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003WO2003094831A2 Novel diazabicyclic biaryl derivatives
11/20/2003WO2003094829A2 Pathogen vaccines and methods for using the same
11/20/2003WO2003094828A2 Cancer vaccines and methods of using the same
11/20/2003WO2003070192A9 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/20/2003WO2003065971A9 Non-myeloablative tolerogenic treatment with tyrphostins
11/20/2003WO2003055915A3 Human netrin receptor and uses thereof
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003049752A3 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
11/20/2003WO2003046124A3 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
11/20/2003WO2003042357A3 Enzymes
11/20/2003WO2003038110A3 7118, a human arginine n-methyltransferase family member and uses therefor
11/20/2003WO2003037272A3 Thymosin alpha 1 peptide/polymer conjugates
11/20/2003WO2003023018A3 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use
11/20/2003WO2003016506A3 Secreted proteins
11/20/2003WO2003016468A3 Antagonistic anti-htnfsf13b human antibodies
11/20/2003WO2003014105A9 Bicyclic compound, production and use as hiv inhibitors
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003008444A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2003000699A8 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
11/20/2003WO2003000021A3 Pancam nucleic acids and polypeptides
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002095011A3 Inactivation of genes of the mep pathway
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002087583B1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/20/2003WO2002083736A3 G-protein coupled receptor molecules and uses thereof
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002064558A3 Oxazole derivatives, their preparation and their use as cytokine inhibitors
11/20/2003WO2002061110A8 Nucleic acid derivatives
11/20/2003WO2002038744A3 Proteases
11/20/2003US20030216586 Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them
11/20/2003US20030216574 Pyrazine based inhibitors of glycogen synthase kinase 3
11/20/2003US20030216571 Tricyclic compounds
11/20/2003US20030216549 Comprises modified chemokine for use as antiinflammatory, viricidal or antiallergenic agent
11/20/2003US20030216546 Genetically engineered fusion proteins for use in diagnosis and treatment of cancer, viral infections, autoimmune and alloimmune diseases
11/20/2003US20030216481 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse
11/20/2003US20030216475 Pharmaceutical composition
11/20/2003US20030216462 Anticancer agents; psoriasis
11/20/2003US20030216450 Inhibitors of dipeptidyl peptidase IV
11/20/2003US20030216440 Process for preparing arylacetylaminothiazoles
11/20/2003US20030216436 Potent, simplified derivatives of immunosuppressive agents
11/20/2003US20030216427 Amine derivatives for the treatment of apoptosis
11/20/2003US20030216417 Substituted anilino-quinoline compounds and use thereof
11/20/2003US20030216413 Catecholamine pharmaceutical compositions and methods
11/20/2003US20030216406 Pyrimidine derivatives
11/20/2003US20030216404 Hydroxamic acid derivatives
11/20/2003US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8
11/20/2003US20030216391 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis
11/20/2003US20030216389 Therapeutic morpholino-substituted compounds
11/20/2003US20030216383 Compounds useful as reversible inhibitors of cysteine proteases
11/20/2003US20030216381 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer
11/20/2003US20030216375 Sulfonamide substituted diphenyl thiourea compounds; use thereof in treating IL-8, GRO alpha, GRO beta, GRO gamma, NAP-2, and ENA-78 mediated diseases
11/20/2003US20030216368 Hormone replacement therapy
11/20/2003US20030216367 In perimenopausal, menopausal, and postmenopausal women through the sequential administration of combinations of conjugated estrogens and trimegestone
11/20/2003US20030216356 Cause the selective destruction of tumour vasculature; are used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis
11/20/2003US20030216343 Expression vectors for stimulating an immune response and methods of using the same
11/20/2003US20030216342 Expression vectors for stimulating an immune response and methods of using the same
11/20/2003US20030216340 Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
11/20/2003US20030216315 Modulation of immune response by non-peptide binding stress response polypeptides
11/20/2003US20030216307 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
11/20/2003US20030215921 Vascular endothelial growth factor-2
11/20/2003US20030215879 Comprise enzymatic polypeptide for use in the treatment of inflammation; aniinflammatory agents
11/20/2003US20030215831 Renal regulatory elements and methods of use thereof
11/20/2003US20030215829 Nuclear hormone receptors
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215792 Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least on neuropeptide
11/20/2003US20030215530 Tea extracts used for prophylaxis of alergies, atopic diseases or skin disorders
11/20/2003US20030215512 Stable glassy state powder formulations
11/20/2003US20030215497 Adjuvant composition and methods for its use
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215495 Antihistamine formulations for soft capsule dosage forms
11/20/2003US20030215467 Isolated from resected and washed human gastrointestinal tract; for oral administration; probiotics
1 ... 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 ... 1172